EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Jonathan Pini iD, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan und 2 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Jonathan Pini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peripheral Nervous System and Muscle Department, Nice University Hospital, Pasteur 2 Hospital, Nice, France. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral, Interleukin-6. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited.

Methods

We analyzed pooled data from two prospective longitudinal cohorts: CTRN‐FSHD France (NCT04038138) and Cytokine FSHD (NCT04694456), each comprising 30 genetically confirmed ambulant FSHD1 patients. Serum IL‐6 levels and clinical assessments were collected at baseline (M0), 12 months (M12), and 18 months (M18); whole‐body muscle MRI (T1‐weighted and STIR sequences) was obtained at M0 and M12. Associations between IL‐6 levels and clinical severity scores, functional measures, and MRI‐derived muscle composition were evaluated.

Results

Serum IL‐6 levels correlated significantly with clinical severity metrics, including Clinical Severity Score, 6‐Minute Walk Test, Manual Muscle Testing, and Motor Function Measure Domain 1 at all time points. Higher IL‐6 levels were associated with increased muscle fat infiltration and free water content compatible with muscle edema on MRI. Longitudinal analyses showed that increases in IL‐6 over 12 months were significantly correlated with changes in T1 (fat infiltration) and STIR (muscle edema) composite scores, reflecting structural and inflammatory disease progression.

Interpretation

These findings validate IL‐6 as a biomarker of FSHD1 severity and underscore its potential as an activity and progression biomarker. The correlation between IL‐6, clinical scores, and MRI‐based muscle composition changes highlights its potential utility for monitoring disease evolution and evaluating therapeutic responses in FSHD1 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralInterleukin-6HumansBiomarkersLongitudinal StudiesMaleFemaleAdultMagnetic Resonance ImagingMiddle AgedSeverity of Illness IndexYoung AdultDisease ProgressionProspective StudiesAdolescentMuscle, Skeletal

Substanzen

Interleukin-6BiomarkersIL6 protein, human

Autor:innen und Institutionen

  • Peripheral Nervous System and Muscle Department, Nice University Hospital, Pasteur 2 Hospital, Nice, France.
  • Institute of Molecular and Cellular Pharmacology, University Cote d'Azur, CNRS, Inserm, Valbonne, France.
  • Princess Grace Hospital Center, Monaco, Monaco.
  • Department of Diagnostic and Interventional Radiology, Nice University Hospital, Pasteur 2 Hospital, Nice, France.
  • University Cote d'Azur, Inserm, CNRS, Institute for Research on Cancer and Aging of Nice (IRCAN), Nice, France.

ORCID-Profile: Jonathan Pini, Sabrina Sacconi

Zitieren

APA

Pini, J., Martinuzzi, E., Dhifallah, S., Slioui, A., Puma, A., Villa, L., Cavalli, M., Ezaru, A., Garcia, J., Gambella, M., Torre, F., Pavan, L. J., Glaichenhaus, N., & Sacconi, S. (2026). Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70210

Vancouver

Pini J, Martinuzzi E, Dhifallah S, Slioui A, Puma A, Villa L, et al. Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70210

BibTeX
@article{Pini2026,
  author = {Pini, Jonathan and Martinuzzi, Emanuela and Dhifallah, Sandra and Slioui, Abderhmane and Puma, Angela and Villa, Luisa and Cavalli, Michele and Ezaru, Andra and Garcia, Jérémy and Gambella, Manuela and Torre, Federico and Pavan, Luca Jacopo and Glaichenhaus, Nicolas and Sacconi, Sabrina},
  title = {Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70210}
}
Kostenlos starten →